torsemide
Trade name: demadex
Approved
Aug 23, 1993
Torasemide is a pyridine-sulfonylurea type loop diuretic mainly used for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and by increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases. — NCATS
Clinical trial activity
42 trials · 71 clinical orgs · 20 marketing orgs
Earliest trial started Mar 1, 2000 (NCT00295542)
Timeline
1990s
2000s
- Jan 1, 2001
Par Pharmaceuticals — Earliest Phase 1 Sponsor(trial)
- May 14, 2002
Teva — Marketing Organization
- May 27, 2003
Par Pharmaceuticals — Marketing Organization
- May 27, 2003
Strides Pharma Science — Marketing Organization
- May 30, 2003
Pliva — Marketing Organization
- Mar 1, 2005
West-Ward Pharmaceutical — Marketing Organization
- Mar 1, 2005
Hikma — Marketing Organization
- May 31, 2005
Apotex — Marketing Organization
- May 31, 2005
Corepharma — Marketing Organization
- May 31, 2005
Impax Laboratories — Marketing Organization
- Oct 17, 2007
Aurobindo Pharma — Marketing Organization
- Feb 26, 2008
Sun Pharmaceuticals — Marketing Organization
- Jan 27, 2009
Hetero Labs Ltd — Marketing Organization
2010s
2020s
- Jun 14, 2021
Sarfez Pharmaceuticals, Inc. — Marketing Organization
- Jun 14, 2021
Sarfe Pharms — Marketing Organization
- Jun 14, 2021
Sarfe Pharms — NDA Secondary Org
Indications
Studied for
- Body Fluids · Phase 4
- Body Weight Changes · Phase 1
- Cardiovascular Diseases · Phase 4
- Diabetes Mellitus, Type 2 · Phase 1
- Drugs, Generic · Phase 1
- Drugs, Investigational · Phase 3
- Edema · Phase 4
- Food-Drug Interactions · Phase 1
- Genetic Predisposition to Disease · Phase 3
- Healthy Volunteers · Phase 3
- Hypertension · Phase 4
- Kidney Failure, Chronic · Phase 1
- Lung Diseases · Phase 4
- Metabolism · Phase 1
- Pharmacokinetics · Phase 3
- Pharmacology · Phase 3
- Pre-Eclampsia · Phase 2
- Renal Insufficiency, Chronic · Phase 4
- Sports Medicine · Phase 1
- Therapeutic Equivalency · Phase 1
- Tricuspid Valve Insufficiency · Phase 4
- Urinary Bladder, Overactive · Phase 2
- Urinary Incontinence · Phase 2
Mechanism of action
SLC12A1 inhibitor
Approval history
- approvedAug 23, 1993
Chemistry & pharmacology
SMILES
CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC2=CC=CC(C)=C2- Mol. weight
- 348.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- WikipediaTorasemide ↗
- NCATSW31X2H97FB ↗
- ChEMBLCHEMBL1148 ↗
Also known as
- 1-isopropyl-3-((4-(3-methylphenylamino)pyridine)-3-sulfonyl)urea
- 1-isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
- 1-isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
- 1-isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
- ac4464
- ac4464
- ac-4464
- ac-4464
- bm-02015
- bm-02015
- demadex
- demadex
- demadex
- demadex
- demadex
- luprac
- luprac
- n-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
- n-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
- toradiur
- torasemida
- torasemida
- torasemide
- torasemide
- torasemide
- torasemide
- torasemide
- torasemide
- torasemide
- torasemide
- torasemidum
- torasemidum
- torem 10
- torem 2.5
- torem 5
- torsemide
- torsemide
- torsemide
- torsemide
- torsemide
- torsemide
- torsemide
- torsemide
- torsemide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07223502 | Phase 3 | Dec 1, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT07201584 | Phase 1 | Sep 5, 2025 | Menarini Group |
| NCT07015671 | Phase 3 | Jul 1, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT07043634 | Phase 3 | Jun 15, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT07046975 | Phase 3 | Jun 15, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT06995144 | Phase 4 | May 28, 2025 | Sarfez Pharmaceuticals, Inc. |
| NCT06670534 | Phase 2 | Jan 31, 2025 | Jemincare |
| NCT06708611 | Phase 4 | Nov 6, 2024 | Sarfez Pharmaceuticals, Inc. |
| NCT06206512 | Phase 2 | Jun 30, 2024 | Sarfez Pharmaceuticals, Inc., The University of Texas, Dallas |
| NCT06362668 | N/A | May 17, 2024 | Reprieve Cardiovascular, Inc |
| NCT06292091 | Phase 1 | Feb 28, 2024 | Seoul National University |
| NCT06176794 | Phase 2 | Jan 31, 2024 | Sarfez Pharmaceuticals, Inc., University of Florida |
| NCT06275763 | Phase 4 | Oct 20, 2023 | Instituto Nacional de Cardiologia de Laranjeiras, Medical University of Warsaw |
| NCT06218199 | Phase 4 | Jul 8, 2021 | Boston Scientific Corporation, Heart Center Research, LLC |
| NCT04921566 | Phase 1 | Jun 5, 2021 | CRO ClinPharmInvest, Pharmtechnology LLC |
| NCT06413082 | Phase 3 | Feb 15, 2021 | Vita-Salute University of Milano. Italy |
| NCT05093621 | Phase 3 | Feb 8, 2021 | Yale University |
| NCT04192110 | Phase 4 | Apr 1, 2020 | Department of Veteran Affairs |
| NCT03296813 | Phase 3 | Aug 14, 2018 | Duke University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT03509545 | Phase 1 | Jul 17, 2018 | Sarfez Pharmaceuticals, Inc., Syngene International |
Organizations
Research & Development (71)
Marketing (23)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Apotex | For profit | MKTG | May 31, 2005 |
| Aurobindo Pharma | For profit | MKTG | Oct 17, 2007 |
| Corepharma | For profit | MKTG | May 31, 2005 |
| Daiichi Sankyo | For profit | MKTG | Apr 21, 2010 |
| Hetero Labs Ltd | For profit | MKTG | Jan 27, 2009 |
| Hikma | For profit | MKTG | Mar 1, 2005 |
| Hikma | For profit | MKTG | Mar 1, 2005 |
| Impax Laboratories | For profit | MKTG | May 31, 2005 |
| Lutipold | For profit | MKTG | Apr 21, 2010 |
| Mylan | For profit | NDA2 | Aug 23, 1993 |
| Mylan | For profit | NDA | Aug 23, 1993 |
| Par Pharmaceuticals | For profit | MKTG | May 27, 2003 |
| Pliva | For profit | MKTG | May 30, 2003 |
| Roche | For profit | NDA2 | Aug 23, 1993 |
| Sankyo | For profit | MKTG | Apr 21, 2010 |
| Sarfe Pharms | For profit | MKTG | Jun 14, 2021 |
| Sarfe Pharms | For profit | NDA2 | Jun 14, 2021 |
| Sarfez Pharmaceuticals, Inc. | For profit | MKTG | Jun 14, 2021 |
| Strides Pharma Science | For profit | MKTG | May 27, 2003 |
| Sun Pharmaceuticals | For profit | MKTG | Feb 26, 2008 |
| Teva | For profit | MKTG | May 14, 2002 |
| Vintage | For profit | MKTG | Mar 22, 2011 |
| West-Ward Pharmaceutical | For profit | MKTG | Mar 1, 2005 |